The Prevalence and Management of Diabetic Nephropathy in Asia (original) (raw)
Article navigation
Review Articles| April 30 2015
Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan
Search for other works by this author on:
Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan
Search for other works by this author on:
Kidney Dis (2015) 1 (1): 52–60.
Abstract
Background: Diabetic nephropathy (DN), especially type 2 diabetes, is now increasing rapidly worldwide, also in Asian countries, and is one of the major long-term vascular complications. The pathogenesis of DN involves both genetic and environmental factors. Around 30-40% of type 2 diabetic patients develop DN despite strict blood glucose and/or blood pressure control. Although it is considered that the genetic background may influence the initiation and progression of DN, the candidate genes are still obscure. Summary: To search for genes that are involved in the susceptibility of DN, a candidate gene approach was taken in the beginning before the development of genome-wide association studies. Although a candidate gene approach can detect rare genetic variants, in advance we need known or presumed pathophysiological knowledge of the specific gene. Investigations using spontaneous animal models are important to determine the pathogenesis and treatment of DN patients. There are many spontaneous animal models, such as the NOD and Akita mice for type 1 diabetes and the Ob/Ob, db/db, Tsumura Suzuki Obese Diabetics, and KK-A y mice for type 2 diabetes. Furthermore, the toxicity of persistent hyperglycemia, the activation of reactive oxygen species, systemic and/or glomerular hypertension, microinflammation, dyslipidemia, and other factors are considered to play important roles. Diabetic patients with normoalbuminuria and normal renal function showed typical histological patterns of DN. The discovery of a specific and reliable diagnostic and prognostic biomarker other than albuminuria is urgently needed and indispensable. Since large clinical trials of oral hypoglycemic drugs in renal failure are lacking, these recommendations will need to be regularly updated after results of larger randomized trials with longer follow-up durations are available. Key Messages: It is necessary to summarize the basic and clinical features of DN patients in Asia and to use these for the treatment of such patients. Facts from East and West: The prevalence of DN is increasing in Asia and Western countries alike. The deletion (D) allele of the angiotensin-converting enzyme gene is associated with progression to end-stage renal disease in Asian patients with DN, but this association is uncertain in Europeans. An association between DN and polymorphism of the gene coding for acetyl coenzyme A carboxylase β has been reported in Asian and Western populations. Both in Japan and the US, criteria for diagnosis are a 5-year history of diabetes and persistent albuminuria. Renal biopsy should be done in patients with severe hematuria, cellular casts and - in the US - hepatitis and HIV to rule out other pathologies. Diabetic retinopathy is considered a key criterion in Japan, but the absence of it does not rule out DN in the US. Enlargement of the kidney is observed as a diagnostic criterion in Japan. The differential use of renal biopsy as diagnostic tool might account for a different prevalence between Asian countries. Some Japanese diabetic patients showed typical histological alterations for DN with a normal ACR and GFR. The clinical classification is similar between Japan and the US including five stages based on ACR and GFR. The Japanese guidelines do not include blood pressure values for the classification of DN. Guidelines for DN treatment are evolving quickly both in Asia and Western countries based on the numerous clinical trials performed worldwide. Targeting the angiotensin system for its hemodynamic and nonhemodynamic effects is a common approach. DPP-4 inhibitors are widely used in Japan and might have a higher glucose-lowering effect in Asian patients due to their specific diet. A randomized, double-blind placebo-controlled study has been launched to assess the efficacy of the Chinese herbal tea extract Shenyan Kangfu in DN.
References
Gohda T, Tomino Y: A paradigm shift for the concept of diabetic nephropathy. Juntendo Med J 2014;60:293-299.
Mooyaart AL: Genetic associations in diabetic nephropathy. Clin Exp Nephrol 2014;18:197-200.
Tomino Y, Makita Y, Shike T, Gohda T, Haneda M, Kikkawa R, Watanabe T, Baba T, Yoshida H: Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients. Nephron 1999;82:139-144.
Gohda T, Makita Y, Shike T, Kobayashi M, Funabiki K, Haneda M, Kikkawa R, Watanabe T, Baba T, Yoshida H, Tomino Y: Association of the DD genotype and development of Japanese type 2 diabetic nephropathy. Clin Nephrol 2001;56:475-480.
Yu ZY, Chen LS, Zhang LC, Zhou TB: Meta-analysis of the relationship between ACE I/D gene polymorphism and end-stage renal disease in patients with diabetic nephropathy. Nephrology 2012;17:480-487.
Tanaka N, Babazono T, Saito S, Sekine A, Tsunoda T, Haneda M, Tanaka Y, Fujioka T, Kaku K, Kawamori R, Kikkawa R, Iwamoto Y, Nakamura Y, Maeda S: Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. Diabetes 2003;52:2848-2853.
Shimazaki A, Kawamura Y, Kanazawa A, Sekine A, Saito S, Tsunoda T, Koya D, Babazono T, Tanaka Y, Matsuda M, Kawai K, Iiizumi T, Imanishi M, Shinosaki T, Yanagimoto T, Ikeda M, Omachi S, Kashiwagi A, Kaku K, Iwamoto Y, Kawamori R, Kikkawa R, Nakajima M, Nakamura Y, Maeda S: Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes 2005;54:1171-1178.
Kamiyama M, Kobayashi M, Araki S, Iida A, Tsunoda T, Kawai K, Imanishi M, Nomura M, Babazono T, Iwamoto Y, Kashiwagi A, Kaku K, Kawamori R, Ng DP, Hansen T, Gaede P, Pedersen O, Nakamura Y, Maeda S: Polymorphisms in the 3′ UTR in the neurocalcin delta gene affect mRNA stability, and confer susceptibility to diabetic nephropathy. Hum Genet 2007;122:397-407.
Maeda S, Kobayashi MA, Araki S, Babazono T, Freedman BI, Bostrom MA, Cooke JN, Toyoda M, Umezono T, Tarnow L, Hansen T, Gaede P, Jorsal A, Ng DP, Ikeda M, Yanagimoto T, Tsunoda T, Unoki H, Kawai K, Imanishi M, Suzuki D, Shin HD, Park KS, Kashiwagi A, Iwamoto Y, Kaku K, Kawamori R, Parving HH, Bowden DW, Pedersen O, Nakamura Y: A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS Genet 2010;6:e1000842.
Kobayashi MA, Watada H, Kawamori R, Maeda S: Overexpression of acetyl-coenzyme A carboxylase beta increases proinflammatory cytokines in cultured human renal proximal tubular epithelial cells. Clin Exp Nephrol 2010;14:15-24.
Wu HY, Wang Y, Chen H, Zhang X, Wang D, Pan Y, Li L, Dai XM: Association of ELMO1 gene polymorphisms with diabetic nephropathy in Chinese population. J Endocrinol Invest 2013;36:298-302.
Lin CJ, Wen MJ, Hung YJ, Pei D, Kuo SW, Hsieh CH: The impact of 5,10-methenyltetrahydrofolate synthetase polymorphism on diabetic nephropathy in the Taiwanese population. Genet Test Mol Biomarkers 2012;16:142-145.
Katsuda Y, Ohta T, Shinohara M, Bin T, Yamada T: Diabetic mouse models. Open J Anim Sci 2013;3:334-342.
Yoshioka M, Kayo CL, Ikeda T, Koizumi A: A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 1997;46:887-894.
Chang JH, Gurley SB: Assessment of diabetic nephropathy in the Akita mouse. Methods Mol Biol 2012;933:17-29.
Gurley SB, Mach CL, Stegbauer J, Yang J, Snow KP, Hu A, Meyer TW, Coffman TM: Influence of genetic background on albuminuria and kidney injury in INS2+/C96Y (Akita) mice. Am J Physiol Renal Physiol 2010;298:F788-F795.
Hong EG, Jung DY, Ko HJ, Zhang Z, Ma Z, Jun JY, Kim JH, Summer AD, Vary TC, Gardner TW, Braonson SK, Kim JK: Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling. Am J Physiol Endocrinol Metab 2007;293:E1687-E1696.
Kondo K, Nozawa K, Tomita T, Ezaki K: Inbred strains resulting from Japanese Mice. Bull Exp Anim 1957;6:107-112.
Nishimura M: Breeding of mice strains for diabetes mellitus. Exp Anim 1969;18:147-157.
Ito T, Tanimoto M, Yamada K, Kaneko S, Matsumoto M, Obayashi K, Hagiwara S, Murakoshi M, Aoki T, Wakabayashi M, Gohda T, Funabiki K, Maeda K, Horikoshi S, Tomino Y: Glomerular changes in the KK-Ay mouse: a possible model for human type 2 diabetic nephropathy. Nephrology 2006;11:29-35.
Moriya T, Suzuki Y, Inomata S, Iwano M, Kanauchi M, Haneda M: Renal histological heterogeneity and functional progress in normoalbuminuric and microalbuminuric Japanese patients with type 2 diabetes. BMJ Open Diabetes Res Care 2014;2:e000029.
Rim TH, Byun IH, Kim HS, Lee SY, Yoon JS: Factors associated with diabetic retinopathy and nephropathy screening in Korea: the Third and Fourth Korea National Health and Nutrition Examination Survey. J Korean Med Sci 2013;28:814-820.
Chong YB, Keng TC, Tan LP, Kong WY, Wong CM, Cheah PL, Looi LM, Tan SY: Clinical predictors of non-diabetic renal disease and role of renal biopsy in diabetic patients with renal involvement: a single center review. Ren Fail 2012;34:323-328.
Macedo CS, Lerco MM, Capelletti SM, Silva RJ, Pinheiro DO, Spadella CT: Reduction of podocytes number in late diabetic alloxan nephropathy: prevention by glycemic control. Acta Cir Bras 2007;22:337-341.
Ishikawa Y, Ito T, Tanimoto M, Hagiwara S, Furukawa M, Yamaguchi S, Omote K, Asanuma K, Gohda T, Shimizu Y, Funabiki K, Horikoshi S, Tomino Y: Podocyte loss and albuminuria of KK-Ay mouse: a spontaneous animal model for human type 2 diabetic nephropathy. J Diab Mellitus 2012;2:346-352.
Gu L, Hagiwara S, Fan Q, Tanimoto M, Kobata M, Yamashita M, Nishitani T, Gohda T, Ni Z, Qian L, Horikoshi S, Tomino Y: Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006;21:299-313.
Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H: Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000;15:1379-1383.
Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, Cullere X, Eckfeldt JH, Doria A, Mayadas TN, Warram JH, Krolewski AS: Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012;23:507-515.
Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, Cullere X, Johnson AC, Crabtree G, Smiles AM, Mayadas TN, Warram JH, Krolewski AS: Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 2012;23:516-524.
Murakoshi M, Tanimoto M, Gohda T, Hagiwara S, Takagi M, Horikoshi S, Tomino Y: Mindin: a novel marker for podocyte injury in diabetic nephropathy. Nephrol Dial Transplant 2011;26:2153-2160.
Murakoshi M, Gohda T, Tanimoto M, Funabiki K, Horikoshi S, Tomino Y: Role of mindin in diabetic nephropathy. Exp Diabetes Res 2011;486305.
Zanchi A, Lehmann, Philippe J: Antidiabetic drugs and kidney disease - recommendations of the Swiss Society for Endocrinology and Diabetology. Swiss Med Wkly 2012;142; w13629, 1-8.
Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM: Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013;56:696-708.
Iwasaki M, Hoshian F, Tsuji T, Hirose N, Matsumoto T, Kitatani N, Sugawara K, Usui R, Kuwata H, Sugizaki K, Kitamoto Y, Fujiwara S, Watanabe K, Hyo T, Kurose T, Seino Y, Yabe D: Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. J Diabetes Investig 2012;3:464-467.
Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M: Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013;36:3460-3468.
Katayama S, Kikkawa R, Isogai S, Sasaki N, Matsuura N, Tajima N, Urakami T, Uchigata Y, Ohashi Y: Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Res Clin Prac 2002;55:113-121.
Imai E, Haneda M, Kobayashi F, Harada A, Ito S, Chan JC , Makino H; ORIENT Study Investigators: Effects of dual blockade of the renin-angiotensin system on the renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension). Hypertens Res 2013;36:1051-1059.
Fried LF, Emanucle N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Relly RF, Seliger SR, Warren SR, Watnick S, Peduzzi P, Guarino P: Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892-1903.
Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-2446.
Na KY, Kim DK, Kim SG, Lee YK, Lim CS: Effect of beraprost sodium on arterial stiffness in patients with type 2 diabetic nephropathy. Trials 2013;14:275.
Wang H, Mu W, Zhai J, Xing D, Miao S, Wang J, Deng Y, Wang N, Chen H, Yang H, He X, Shang H: The key role of Shenyan Kangfu tablets, a Chinese patent medicine for diabetic nephropathy: study protocol for a randomized, double-blind and placebo-controlled clinical trial. Trials 2013;14:165.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Digital Version
Pay-Per-View Access
$45.00
1 Karger Article Bundle Token
$170
Rental
This article is also available for rental through DeepDyve. 